20:13 , Jan 26, 2018 |  BC Week In Review  |  Clinical News

Fortress' Caelum subsidiary reports MTD for CAEL-101 in AL amyloidosis

The Caelum Biosciences Inc. subsidiary of Fortress Biotech Inc. (NASDAQ:FBIO) said data from a U.S. Phase Ia/Ib trial established 500 mg/m 2 as the maximum tolerated dose (MTD), the primary endpoint, of CAEL-101 (11-1F4) to...
21:00 , May 17, 2017 |  BC Week In Review  |  Clinical News

Fortress completes Phase I enrollment of amyloidosis candidate CAEL-101

Fortress Biotech Inc. (NASDAQ:FBIO) completed enrollment of about 42 patients in a Phase Ia/Ib trial of IV CAEL-101 (11-1F4) to treat amyloid light-chain (AL) amyloidosis. The open-label, dose-escalation, U.S. trial is determining the maximum tolerated...
21:37 , Jan 6, 2017 |  BC Week In Review  |  Company News

Columbia University, Fortress Biotech deal

The university granted Fortress’ newly formed Caelum Biosciences Inc. subsidiary exclusive, worldwide development and commercialization rights to CAEL-101 . The chimeric fibril-reactive mAb is in Phase I testing to treat amyloid light-chain amyloidosis. The partners...